Guggenheim Initiates Coverage On LB Pharmaceuticals with Buy Rating, Announces Price Target of $80

Benzinga Newsdesk www.benzinga.com Positive 63.3%

Neg 0% Neu 0% Pos 63.3%

Guggenheim analyst Delma Caiati initiates coverage on LB Pharmaceuticals (NASDAQ:LBRX) with a Buy rating and announces Price Target of $80.